Flotufolastat F-18

氟[18F]妥司特

Report date: 2026/04/16 20:00:17
NME

Base Information

Drug NameFlotufolastat F-18
Drug Alias NameFluorine F 18 radiohybrid PSMA-7.3Fluorine F 18 rhPSMA-7.3Fluorine-18 rhPSMA-7.3POSLUMA18F-rhPSMA-7.3 +[11] 
ClassificationRadiation-emitting products > Radioactive diagnostic agentDiagnostic agent (In vivo) > Radionuclide Imaging agentSmall molecules > Heterocyclic drugs +[5] 
Mechanisms of ActionPositron-emission tomography enhancersRadionuclide imaging enhancersProstate-Specific Membrane Antigen modulators
TargetsProstate-Specific Membrane Antigen
Therapy Area/IndicationsContrast agentsProstatic Neoplasms
Global Approved IndicationsProstatic Neoplasms
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2023/05/25
Country/TerritoryUnited StatesNetherlandsGermany +[5] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesTechnical University MunichBlue Earth Diagnostics Inc
China Registration ClassN/A

Develop Information

Active CompaniesBlue Earth DiagnosticsBlue Earth Diagnostics LtdBeijing Xiantong International Technology Co Ltd
Inactive CompaniesMidLantic Urology LLCIcahn School Of Medicine At Mount SinaiThe University Of Texas MD Anderson Cancer Center +[6] 
Active IndicationsContrast agentsProstatic Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A